Khartis debuts with $95 million and an oral shot at thyroid eye disease
USA-based Khartis Therapeutics has come out of stealth with $95 million raised to date and a plan to develop an oral pill for thyroid eye disease (TED), a market currently served only by antibodies given by intravenous infusion. The San Diego biotech announced the debut on Thursday.
The total includes $50 million in a newly closed series B led by Forge Life Science Partners, with Longwood Fund and Alexandria Venture Investments joining existing backers Foresite Capital, Lilly Asia Ventures and Nextech Invest. The company was originally incubated inside Foresite Labs and was founded in 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze